Starting gliflozin early in the emergency room for older adults with worsening heart failure
Tests starting gliflozin early in older adults with worsening chronic heart failure.
Key facts
- Who runs it
- Centre Hospitalier Regional Universitaire
- Where
- Besancon Cedex, Colmar Cedex, Dijon, Reims Cedex, Strasbourg, and Trévenans, FranceSee the 6 sites
- Trial code
- Registry title
- GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE ADMITTED IN THE EMERGENCY ROOM - A FEASIBILITY STUDY
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 144 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional
- Record updated
- 31 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 75 or older who came to the emergency department with worsening chronic heart failure and are not yet taking a gliflozin.
- Age
- 75 years or older (the record also lists a minimum age of 65 years).
- Sex
- Women and men can join.
- Disease stage
- Acute worsening of chronic heart failure, with signs of fluid build-up, high natriuretic peptide blood levels (BNP or NT-proBNP), and a need for stronger treatment on admission. Hospital admission is being considered.
- Earlier treatment
- Must not already be taking a gliflozin (empagliflozin or dapagliflozin).
- Biomarker or test result
- BNP 400 pg/mL or higher, or NT-proBNP 1,600 pg/mL or higher, in sinus rhythm. With atrial fibrillation: BNP 600 pg/mL or higher, or NT-proBNP 2,400 pg/mL or higher.
Main reasons for not taking part
- Type 1 diabetes
- Chronic kidney disease with filtration rate below 25 ml/min/1.73 m²
- Cardiogenic shock or acute coronary syndrome
- Severe valve disease that may need surgery during the study
- Finally admitted to cardiology, or sent home or to a care home
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Male or female, age ≥ 75 years
- Admitted to the emergency department for acute decompensated heart failure, diagnosed by the emergency physician based on a range of factors including: (i) Worsening symptoms of chronic heart failure - worsening dyspnea or dyspnea at rest - progressive asthenia - weight gain - worsening of edema/abdominal distension/anasarca (ii) AND objective signs or diagnostic tests consistent with peripheral and/or pulmonary congestion - jugular venous distension - bilateral crackles on pulmonary auscultation - presence of S3 gallop on cardiac auscultation - ascites - hepatomegaly - peripheral edema - radiological and/or ultrasound signs of pulmonary congestion - dilatation of the inferior vena cava (iii) AND elevated natriuretic peptides (BNP or NT-proBNP): a. For patients in sinus rhythm: BNP ≥ 400 pg/mL or NT-proBNP ≥ 1,600 pg/mL b. For patients with atrial fibrillation: BNP ≥ 600 pg/mL or NT-proBNP ≥ 2,400 pg/mL) (iv) AND need for treatment intensification upon admission (increased doses of oral diuretics, addition of a second diuretic, or initiation of intravenous diuretic therapy)
- Patients considered for hospitalization
- No pre-existing treatment with gliflozins (empagliflozin or dapagliflozin)
- Signed and dated informed consent
Who cannot take part
- Presence of acute coronary syndrome on ECG or within 30 days prior to randomization,
- Percutaneous or surgical coronary intervention planned or performed within 30 days prior to randomization,
- Type 1 diabetes,
- Any other medical condition that would put the patient at risk or could influence the results of the study,
- Chronic kidney disease (glomerular filtration rate < 25 ml/min/1.73 m²),
- Any severe valvular heart disease that may require surgery during the study
- Known intolerance or history of hypersensitivity to the active substance or any of the excipients in the medication
- Persons subject to legal protection measures, psychiatric care, persons admitted to a health or social care facility,
- Individuals unable to express consent, follow instructions, or comply with follow-up procedures,
- Not affiliated with or not a beneficiary of a French social security system,
- Subject is in the exclusion period of another study or listed in the “national volunteer registry.”
- The patient is finally referred and admitted to the Cardiology Department
- The patient is ultimately referred to return home or to a residential care facility for dependent elderly people
- Cardiogenic shock,
- Persons deprived of liberty,
Where in France
- Centre Hospitalier Regional UniversitaireBesancon Cedex, FranceNot yet recruiting
- Centre Hospitalier De ColmarColmar Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de DijonDijon, FranceNot yet recruiting
- Centre Hospitalier Universitaire ReimsReims Cedex, FranceNot yet recruiting
- Les Hopitaux Universitaires de StrasbourgStrasbourg, FranceNot yet recruiting
- Hôpital Nord Franche-ComtéTrévenans, FranceNot yet recruiting
About the trial
What the trial wants to find out
Assess the overall feasibility of a prospective randomized study comparing early initiation of gliflozin treatment with telephone counseling in the emergency department with standard care in elderly patients admitted to the emergency department for decompensated chronic heart failure and not treated with gliflozins.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE ADMITTED IN THE EMERGENCY ROOM - A FEASIBILITY STUDY
- Plain-language title
- Starting gliflozin early in the emergency room for older adults with worsening heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 31 March 2026